688553 汇宇制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.580-0.6458.3983.7336.844
总资产报酬率 ROA (%)0.431-0.4906.6063.1195.924
投入资产回报率 ROIC (%)0.480-0.5477.3413.4716.657

边际利润分析
销售毛利率 (%)79.17679.60383.41485.92988.202
营业利润率 (%)5.940-6.63531.83813.41515.767
息税前利润/营业总收入 (%)7.147-11.32929.9339.74612.824
净利润/营业总收入 (%)8.068-3.06028.86515.02916.674

收益指标分析
经营活动净收益/利润总额(%)165.530-115.61525.10740.37979.263
价值变动净收益/利润总额(%)-121.760258.93272.54030.73918.969
营业外收支净额/利润总额(%)3.143-2.9730.3625.8921.235

偿债能力分析
流动比率 (X)2.6092.6872.9423.2645.458
速动比率 (X)2.3872.4632.8013.0905.143
资产负债率 (%)26.50425.35223.08019.44713.058
带息债务/全部投入资本 (%)16.09814.44812.78210.2951.708
股东权益/带息债务 (%)508.481578.047672.970863.9905,704.069
股东权益/负债合计 (%)278.138295.327333.743413.795665.802
利息保障倍数 (X)7.0472.319-14.809-2.161-4.083

营运能力分析
应收账款周转天数 (天)29.50626.37318.07019.1796.594
存货周转天数 (天)437.490374.572310.428440.314352.322